Facilities Visits. Representatives of Dyax and Genzyme may visit all manufacturing sites and the sites of any clinical trials or other experiments being conducted by the other Party, Kallikrein LLC or a Third Party in connection with the Development Program. If requested by the other Party, Dyax and Genzyme shall cause appropriate individuals working on the Development Program to be available for meetings at the location of the facilities where such individuals are employed at times reasonably convenient to the Party responding to such request.
Facilities Visits. Representatives of each Party, its Affiliates, or any applicable regulatory authority (including without limitation the FDA and the EMEA) may visit, upon reasonable notice and in the presence of the other Party, all manufacturing sites and the sites of any clinical trials or other experiments being conducted by the other Party and its Permitted Subcontractors in connection with the Development Program. Each Party shall, upon request of the other Party, cause appropriate individuals working on the Development Program on its and its Permitted Subcontractors’ behalf to be available for meetings at the location of the facilities where such individuals are employed at times reasonably convenient to the Party responding to such request.
Facilities Visits. Representatives of Diacrin and Genzyme may visit all manufacturing sites and the sites of any clinical trials or other experiments being conducted by the other Party or Diacrin/Genzyme LLC in connection with the Development Program. If requested by the other Party, Diacrin and Genzyme shall cause appropriate individuals working on the Development Program to be available for meetings at the location of the facilities where such individuals are employed at times reasonably convenient to the Party responding to such request.
Facilities Visits. Representatives of GelTex and Genzyme may visit all manufacturing sites and the sites of any clinical trials or other experiments being conducted by the other Parties in connection with the Development Program. If requested by the other Party, GelTex and Genzyme shall cause appropriate individuals working on the Development Program to be available for meetings at the location of the facilities where such individuals are employed at times reasonably convenient to the Party responding to such request.
Facilities Visits. Representatives of GTC and Genzyme may visit all manufacturing sites and the sites of any clinical trials or other experiments being conducted by the other Party or ATIII LLC in connection with the Development Program. If requested by the other Party, GTC and Genzyme shall cause appropriate individuals working on the Development Program to be available for meetings at the location of the facilities where such individuals are employed at times reasonably convenient to the Party responding to such request.
Facilities Visits. Any Union representative shall give notice to the Fire Chief when visiting employees at their assigned fire stations and fire administration during the employee’s duty period, provided that solicitation for membership or other internal employee organization business shall be conducted only during the off-duty hours of all employees concerned. The Fire Chief and the Union may enter into a standing agreement for routine contact between Union representatives and on-duty employees and such agreement shall continue until revoked.
Facilities Visits. DENDREON shall have the right to visit DIOSYNTH’S facilities in accordance with the guidelines set forth in Schedule 5 attached to this Agreement. DENDREON agrees to comply with these guidelines and shall bear responsibility for any failure of its representatives to so comply.
Facilities Visits. Bayer shall have the right during normal business hours to visit Gen-Probe facilities (or subcontractor's facilities) to conduct quality audits, evaluations and review the performance of Gen-Probe's obligations under this Agreement. Bayer shall also have the right to meet with Gen-Probe's personnel and review development, production, process, and quality records relevant to the subject matter in this Agreement, subject to the confidentiality provisions of the Basic Agreement. Bayer shall provide reasonable notice to Gen-Probe prior to each such visit. Bayer will not copy records without Gen-Probe agreement. Gen-Probe's agreement regarding copying will not be unreasonably withheld. Execution Copy of Development, April 2, 2001 Distribution and Licensing Agreement Page 11
Facilities Visits. During the term of this Agreement, CIMA shall allow personnel of Organon, at Organon's expense, to visit the manufacturing and research facilities of CIMA and to consult with CIMA personnel, at mutually agreeable times, to discuss and review the development of the Products.
Facilities Visits. During the term of this Agreement, CIMA shall allow personnel of IPR and/or Zeneca Limited, at IPR's expense, to visit the manufacturing and research facilities of CIMA and to consult with CIMA personnel, at mutually agreeable times and upon reasonable notice, to discuss and review the development of the Product, PROVIDED, HOWEVER, that such personnel shall not be permitted to visit any area of the manufacturing and research facilities of CIMA which contain confidential information or materials of a third party which cannot be removed or protected from such personnel's view. However, CIMA acknowledges that infrequently for regulatory or similar compliance reasons, all areas of the manufacturing and research facilities of CIMA may need to be visited and inspected by such personnel and CIMA shall use all reasonable commercial efforts to manage its manufacturing and site arrangements to permit such "all areas" visits and inspections, but CIMA shall not be required by virtue of this provision or otherwise to breach any confidentiality or other provisions in its agreements with any third party.
